RNAZTranscode Therapeutics, Inc.同业对比
Transcode Therapeutics, Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNAZ本股 | $5M#12 | — | 4.0x#13 | — | — | -106.9%#16 | — | -2769.7%#14 | — | — | -51.6%#5 | — |
| PCSA | $6M#7 | — | 2.3x#10 | — | — | 214.5%#1 | — | 533.8%#1 | -1263.2%#3 | — | -60.0%#6 | 0.7%#1 |
| RCKTW | $5M#8 | — | 0.0x#1 | — | — | 13.8%#9 | — | -93.7%#3 | — | — | 11.4%#1 | — |
| GOVX | $5M#9 | — | 3.1x#11 | 2.2x#4 | -37.1%#4 | 14.1%#8 | -869.3%#5 | -1219.1%#13 | — | — | -96.0%#15 | — |
| PRPH | $5M#11 | — | — | 1.2x#2 | -35.8%#3 | 72.4%#3 | -415.4%#2 | — | -367.7%#1 | — | -89.8%#12 | — |
| CVKD | $6M#6 | — | 3.2x#12 | — | — | -24.3%#14 | — | -736.6%#12 | -15644.2%#6 | — | -82.6%#11 | — |
| APVO | $5M#10 | 0.0x#1 | 0.4x#3 | 1.7x#3 | -74.7%#6 | -7.6%#13 | -845.0%#4 | -223.6%#9 | -4845.7%#5 | — | -91.7%#13 | — |
| INM | $5M#13 | — | 0.7x#5 | 1.0x#1 | 7.5%#2 | -6.3%#11 | -160.8%#1 | -118.4%#7 | -451.0%#2 | — | -40.0%#4 | — |
| ADIL | $7M#3 | — | 1.9x#9 | — | — | 39.6%#5 | — | -214.6%#8 | — | — | -70.7%#8 | — |
| DRMA | $5M#14 | — | 0.7x#6 | — | — | 38.5%#6 | — | -117.9%#6 | — | — | -81.1%#10 | — |
| CNSP | $8M#2 | — | 119.9x#15 | — | — | -6.7%#12 | — | -22417.9%#15 | — | — | -29.7%#2 | — |
| FBLG | $5M#15 | 0.2x#2 | 1.0x#8 | — | — | -67.1%#15 | — | -402.2%#11 | -1409.7%#4 | — | -94.5%#14 | — |
| TRAW | $7M#4 | — | 0.6x#4 | 2.4x#5 | 1134.5%#1 | 105.5%#2 | -640.7%#3 | 79.2%#2 | — | — | -69.5%#7 | — |
| RVPH | $5M#16 | — | 0.3x#2 | — | — | 33.6%#7 | — | -113.9%#5 | — | — | -96.2%#16 | — |
| TCRT | $46M#1 | — | 35.5x#14 | 9133.9x#6 | -50.0%#5 | 10.8%#10 | -84500.0%#6 | -324.2%#10 | — | — | -35.1%#3 | — |
| ACXP | $6M#5 | — | 0.9x#7 | — | — | 43.5%#4 | — | -113.6%#4 | — | — | -79.2%#9 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-08-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议